Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04950075 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of INBRX-109 in Conventional Chondrosarcoma

Study acronym: ChonDRAgon
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv48
  2. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 201 to confirmed 206 · Study sites: 58 to 68 · Primary completion date changed from estimate of Sep 2025 to Sep 30, 2025v47 Show 3 more changesShow less
    • Enrollment target: estimated 201 to confirmed 206
    • Study sites: 58 to 68
    • Primary completion date changed from estimate of Sep 2025 to Sep 30, 2025
  3. Primary completion date: Dec 2024 to Sep 2025 Primary endpoint revised · Study sites: 54 to 58 · Completion date: Jul 2025 to Dec 2026 · 1 morev46 Show 4 more changesShow less
    • Primary endpoint revised
    • Study sites: 54 to 58
    • Completion date: Jul 2025 to Dec 2026
    • Secondary endpoints revised (9)

    See this version in full on ClinicalTrials.gov ↗

  4. Completion date: Jun 2025 to Jul 2025 Site contacts updated at 53 of 54 sitesv45 Show 1 more changeShow less
    • Site contacts updated at 53 of 54 sites
  5. Study sites: 55 to 54v44
Show 42 earlier versionsHide 42 earlier versions
  1. Site contacts updated at 1 of 55 sitesv43
  2. 2 versions Re-verified since Feb 20, 2024, no change to tracked fieldsv41-v42
  3. Primary completion date: Feb 2024 to Dec 2024 Completion date: Jun 2024 to Jun 2025v40 Show 1 more changeShow less
    • Completion date: Jun 2024 to Jun 2025
  4. Site details revised at 1 of 55 sitesv39
  5. Study sites: 62 to 55v38
  6. Site contacts updated at 1 of 62 sitesv37
  7. Site details revised at 2 of 62 sitesv36
  8. Site details revised at 1 of 62 sitesv35
  9. Site details revised at 2 of 62 sitesv34
  10. Study sites: 61 to 62v33
  11. Site contacts updated at 5 of 61 sitesv32
  12. Study sites: 51 to 61v31
  13. Study sites: 49 to 51v30
  14. Site details revised at 1 of 49 sitesv29
  15. Re-verified, no change to tracked fieldsv28
  16. Study sites: 51 to 49 Eligibility criteria expanded, about 11 words · Secondary endpoints revised (9)v27 Show 2 more changesShow less
    • Eligibility criteria expanded, about 11 words
    • Secondary endpoints revised (9)

    See this version in full on ClinicalTrials.gov ↗

  17. Site details revised at 1 of 51 sitesv26
  18. Site details revised at 2 of 51 sitesv25
  19. Site details revised at 1 of 51 sitesv24
  20. Site details revised at 2 of 51 sitesv23
  21. Study sites revised (51)v22 See this version in full on ClinicalTrials.gov ↗
  22. Site details revised at 1 of 51 sitesv21
  23. Site details revised at 1 of 51 sitesv20
  24. Site details revised at 2 of 51 sitesv19
  25. Site details revised at 1 of 51 sitesv18
  26. Site details revised at 2 of 51 sitesv17
  27. Site details revised at 3 of 51 sitesv16
  28. Site contacts updated at 2 of 51 sitesv15
  29. Site details revised at 6 of 51 sitesv14
  30. Site details revised at 7 of 51 sitesv13
  31. Site details revised at 7 of 51 sitesv12
  32. Site details revised at 5 of 51 sitesv11
  33. Study sites: 50 to 51v10
  34. Site details revised at 4 of 50 sitesv9
  35. Re-verified, no change to tracked fieldsv8
  36. Site details revised at 2 of 50 sitesv7
  37. Site contacts updated at 1 of 50 sitesv6
  38. Study sites: 29 to 50v5
  39. Study sites: 1 to 29v4
  40. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Aug 2021 to Sep 23, 2021v3 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Aug 2021 to Sep 23, 2021
  41. Study title shortened, about 2 wordsv2 See this version in full on ClinicalTrials.gov ↗
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Inhibrx
4 trials monitored
See 1 trial at risk
Sarcoma
951 trials monitored
See 56 trials at risk
Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.
Trial Details
NCT Number NCT04950075
Lead Sponsor Inhibrx Biosciences, Inc
Conditions Conventional Chondrosarcoma
Enrollment 206 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov